Skip to main content
S.M.A.I.O logo

S.M.A.I.O — Investor Relations & Filings

Ticker · ALSMA ISIN · FR0014005I80 LEI · 969500T1Z0DAZXPZMC93 PA Manufacturing
Open in API
Filings indexed 114 across all filing types
Latest filing 2022-06-15 Regulatory Filings
Country FR France
Listing PA ALSMA

About S.M.A.I.O

https://smaio.com/

S.M.A.I.O. (Software, Machines and Adaptative Implants in Orthopaedics) is a medical device manufacturer that develops solutions for spine surgery. The company provides a comprehensive platform, I-Kontrol, which incorporates planning software, adaptive implants, and related services for spine surgeons. This integrated solution is designed to enhance control over surgical procedures to improve safety, performance, and repeatability. The I-Kontrol platform covers the entire surgical workflow, including pre-operative planning (i-PLAN), surgical execution with implants (i-PERFORM), post-operative outcome analysis (i-CHECK), and training programs (i-LEARN). S.M.A.I.O. utilizes clinical data, imaging, and artificial intelligence to advance the treatment of vertebral conditions.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from SMAIO announcing the receipt of a 510(k) clearance from the FDA for its 'K-rod' product. This type of announcement, detailing regulatory milestones, product approvals, and strategic updates, is typically classified as a general corporate announcement or regulatory update. It is not a full Annual Report (10-K), an Earnings Release (ER), an Interim Report (IR), or a specific management discussion (MDA). Since it is a specific, material announcement that doesn't fit the highly specialized categories like Director's Dealing (DIRS) or Capital Change (CAP), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for material corporate news that isn't covered elsewhere, or potentially an Earnings Release (ER) if it were focused on financial results, which it is not. Given the focus on FDA clearance, RNS is the most appropriate general regulatory announcement code.
2022-06-15 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that TP ICAP Midcap has initiated coverage of SMAIO shares with a 'Buy' recommendation. It also lists upcoming financial events, including the 'Shareholders' AGM' and 'Publication of H1 2022 sales'. This type of announcement, which disseminates news about analyst coverage, upcoming events, or general corporate updates outside of mandatory periodic financial filings (like 10-K or IR), typically falls under general regulatory announcements or news releases. Since it is not a full report (10-K, IR), a specific financial event report (ER, DIV), or a management change (MANG), the most appropriate general category for this type of market-moving news release that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory announcements.
2022-06-08 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is a press release from SMAIO dated June 8, 2022, announcing that TP ICAP Midcap has initiated research coverage on the stock with a 'buy' recommendation and a target price. This type of announcement, which details the initiation of analyst coverage, does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). It is an announcement related to investor relations and market coverage. Since it is not a formal regulatory filing like a Director's Dealing (DIRS) or a Major Shareholding Notification (MRQ), and it is not a presentation (IP) or a transcript (CT), the most appropriate classification is the general 'Regulatory Filings' fallback category (RNS), as it is a public announcement intended for the market regarding external analysis, which often falls under general regulatory disclosure requirements when a more specific category is unavailable. Given the short length and announcement nature, RNS is preferred over a specific report type.
2022-06-08 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated June 2, 2022, announcing that the company SMAIO obtained the FDA 510(k) clearance for its Balance Analyzer 3D surgical planning software. This is a significant business/regulatory update concerning product approval in the US market, which is not covered by standard financial reports (10-K, IR, ER) or specific corporate actions like dividends or director dealings. It is an announcement of a key operational/regulatory milestone. Since it is not a standard financial report, a management discussion, or a specific corporate event like a merger or AGM, it falls best under the general category for regulatory announcements or significant operational news that doesn't fit elsewhere. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a significant, non-standard regulatory achievement announcement, although 'Capital/Financing Update' (CAP) or 'Legal Proceedings Report' (LTR) are clearly incorrect. It is an announcement, not a full report, making RPA less likely as it's not announcing the publication of a financial report. Therefore, RNS is the best fit for a major regulatory clearance announcement.
2022-06-02 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated June 2, 2022, announcing that SMAIO received FDA 510(k) clearance for its Balance Analyzer 3D software. It discusses a major step in their market penetration strategy and mentions upcoming financial events like the Shareholders' AGM and the publication of H1 2022 sales. This type of announcement, which details significant operational or regulatory achievements but is not a formal periodic report (like 10-K or IR), is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were focused purely on results. Since it is a specific, material, non-financial-result announcement (FDA clearance), and it is not a formal report itself, RNS is the most appropriate general regulatory category. The document length (4591 chars) is short enough that it might be considered an announcement of news rather than the full report, fitting the RPA/RNS criteria, but RNS is the best fit for general material news updates.
2022-06-02 English
Rapports financiers et d'audit annuels / Rapport financier annuel
Management Reports Classification · 1% confidence The document is a 'Rapport de gestion du Conseil d'Administration' (Management Report) for the Annual General Meeting (AGM) of S.M.A.I.O. It details the company's activity, financial situation for the fiscal year ending December 31, 2021, and significant events post-closing (such as the IPO and partnership with NuVasive). While it contains management's analysis, it is specifically prepared for the AGM as part of the mandatory reporting package. According to the provided definitions, this fits the 'Management Reports' (MDA) category, which covers management's detailed explanation of financial results, business trends, and outlook. FY 2021
2022-04-29 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.